Quick Answer
Voyager Therapeutics, Inc. reported Net Income Loss of -$119.72 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed a decrease of -84.2% in Net Income Loss from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Voyager Therapeutics, Inc.'s Net Income Loss has declined by 633.7%.
- Historical annual values: Fiscal year 2025: -$119.72 million | Fiscal year 2024: -$65.00 million | Fiscal year 2023: $132.33 million | Fiscal year 2022: -$46.41 million | Fiscal year 2021: -$71.20 million | Fiscal year 2020: $36.74 million | Fiscal year 2019: -$43.60 million | Fiscal year 2018: -$88.29 million | Fiscal year 2017: -$70.70 million | Fiscal year 2016: -$40.19 million | Fiscal year 2015: -$29.67 million | Fiscal year 2014: -$16.32 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: